Antiviral use in liver function abnormalities and Covid-19 patients: Serial cases

Intan Rizkia Dewi, Ummi Maimunah

Research output: Contribution to journalArticlepeer-review


Introduction: Some SARS-CoV-2 patients have liver function abnormalities due to anti-viral drug effects. Methods: The design of this study was a case series reported using retrospectives. Data collection was carried out from December 2020 to February 2021. All participants were diagnosed with SAR-CoV-2 and received an anti-viral drug which identified liver function abnormalities. Results: The patients’ average age was 54.56 ± 14.46 years old. Most patients experienced shortness of breath and cough, with hypertension as the accompanying comorbid. Increased AST and ALT were found in one patient who used Lopinavir-Ritonavir. The increase was 1.0 times to 2.0 times the expected value. Increased CRP, D-dimer and procalcitonin were also found, with a mean of 12.27 ± 15,34, 1861.29 ± 1828.85 and 1.54 ± 2.84, respectively. One of the patients in the Lopinavir-Ritonavir group died while receiving treatment. Conclusion: SAR-CoV-2 is one of the risk factors that cause liver function abnormalities supported by anti-viral drugs that cause liver work to increase.

Original languageEnglish
Article number104876
JournalAnnals of Medicine and Surgery
Publication statusPublished - Dec 2022


  • Anti-viral drug
  • COVID-19 disease
  • Favipiravir
  • Lopivia
  • Remdesivir


Dive into the research topics of 'Antiviral use in liver function abnormalities and Covid-19 patients: Serial cases'. Together they form a unique fingerprint.

Cite this